December 13, 2008 |
Bristol-Myers Squibb Co. and Sanofi-Aventis won an appeals court ruling Friday that will help them block generic competition to the blood thinner Plavix, the world's No. 2 selling-drug, in the U.S. until 2011. Bristol-Myers and Sanofi said that as a result of the ruling by a three-judge panel of the U.S. Court of Appeals for the Federal Circuit in Washington, they will seek reimbursement from Canadian drug maker Apotex Inc.
September 17, 2008 |
The government closed U.S. borders Tuesday to more than 30 generic drugs -- including popular antibiotics and cholesterol medicines -- made by India's biggest pharmaceutical company, citing poor quality in two of its factories. The Food and Drug Administration's move doesn't end U.S. sales by Ranbaxy Laboratories Ltd. Instead, it blocks imports of generic drugs -- including generic versions of the antibiotic Cipro and the cholesterol pill Zocor -- as well as pharmaceutical ingredients made at the suspect plants.
August 28, 2008 |
Medicare overpaid for drugs that had generic versions because of a time lag in computing prices from when the cheaper medicines became available, the U.S. Health and Human Services Department's inspector general said. Payments for cancer drug irinotecan, sold by Pfizer Inc. as Camptosar, remained at more than double the average manufacturer's sales price after the generic version was cleared for sale Feb. 20, said the report, released Tuesday. Medicare, the health insurance program for the elderly and disabled, would have saved $6.5 million in March had it factored the generic price into its rate.
April 20, 2008 |
A cheaper, generic version of GlaxoSmithKline's Wellbutrin XL antidepressant is just as safe and effective as the original drug, despite complaints from some patients, the Food and Drug Administration said. The FDA said it received 85 reports from patients who switched from Wellbutrin XL to a cheaper generic by Teva Pharmaceutical Industries and Impax Laboratories Inc., including 78 who said they slipped back into depression. Agency scientists reviewed versions of the two drugs and found the data did not show the problems stemmed from any differences between them.
February 22, 2008 |
Watson Pharmaceuticals Inc. won clearance to sell the first generic version of Pfizer Inc.'s cancer drug Camptosar. The Food and Drug Administration approved Watson's generic irinotecan hydrochloride after patents on the brand-name drug expired. Corona-based Watson said it was entitled to 180 days of market exclusivity before the FDA could approve another generic.
February 6, 2008 |
Watson Pharmaceuticals Inc. will begin shipping generic versions of Merck & Co.'s osteoporosis drug Fosamax. Merck will make and supply the drug and receive a share of the profit in the U.S., Corona-based Watson said. Sales of Fosamax dropped 3% to $3 billion last year, Whitehouse, N.J.-based Merck reported Jan. 30. The drug is expected to lose market exclusivity at the close of business today, according to Watson.